OBJECTIVE: Adiponectin and resistin have been linked to inflammation, endothelial dysfunction, and/or insulin secretion or resistance. It remains to be elucidated which of these adipokines is associated primarily with biomarkers of all or only some of these categories, i.e. biomarkers of inflammation, endothelial dysfunction, and/or insulin secretion or insulinemia. DESIGN AND METHODS: We studied 1065 healthy women, Nurses' Health Study participants, who provided blood samples in 1989-1990. A cross-sectional analysis was conducted to assess the relationships between total and high-molecular weight (HMW) adiponectin and resistin with inflammatory markers and biomarkers of endothelial dysfunction, insulin secretion, and insulinemia. RESULTS: Resistin was positively associated with the inflammatory markers soluble tumour necrosis factor-alpha receptor II and interleukin-6 but not with any biomarkers of endothelial function, glycemia, insulinemia, or markers of insulin secretion after multivariate adjustment for age and body mass index (BMI). In both crude and multivariate analyses, total adiponectin was inversely associated with insulin, proinsulin, C-peptide, HbA1c, sE-selectin, and C-reactive protein (CRP) levels. HMW adiponectin was inversely associated with circulating insulin, proinsulin, C-peptide, HbA1c, sE-selectin, and CRP concentrations, even after adjustment for age, BMI, lifestyle factors, exercise, the use of medications as well as the other biomarkers of interest. Total and HMW adiponectin demonstrated negative associations with soluble intercellular adhesion molecule-1, which became nonsignificant after adjustment for confounders, whereas positive associations between soluble vascular cell adhesion molecule-1 and total adiponectin became significant only after multivariate adjustment. CONCLUSIONS: Total and HMW adiponectin are inversely associated with markers of insulin secretion/insulinemia, endothelial function, and inflammation. Resistin is positively associated only with markers of inflammation.
OBJECTIVE:Adiponectin and resistin have been linked to inflammation, endothelial dysfunction, and/or insulin secretion or resistance. It remains to be elucidated which of these adipokines is associated primarily with biomarkers of all or only some of these categories, i.e. biomarkers of inflammation, endothelial dysfunction, and/or insulin secretion or insulinemia. DESIGN AND METHODS: We studied 1065 healthy women, Nurses' Health Study participants, who provided blood samples in 1989-1990. A cross-sectional analysis was conducted to assess the relationships between total and high-molecular weight (HMW) adiponectin and resistin with inflammatory markers and biomarkers of endothelial dysfunction, insulin secretion, and insulinemia. RESULTS:Resistin was positively associated with the inflammatory markers soluble tumour necrosis factor-alpha receptor II and interleukin-6 but not with any biomarkers of endothelial function, glycemia, insulinemia, or markers of insulin secretion after multivariate adjustment for age and body mass index (BMI). In both crude and multivariate analyses, total adiponectin was inversely associated with insulin, proinsulin, C-peptide, HbA1c, sE-selectin, and C-reactive protein (CRP) levels. HMW adiponectin was inversely associated with circulating insulin, proinsulin, C-peptide, HbA1c, sE-selectin, and CRP concentrations, even after adjustment for age, BMI, lifestyle factors, exercise, the use of medications as well as the other biomarkers of interest. Total and HMW adiponectin demonstrated negative associations with soluble intercellular adhesion molecule-1, which became nonsignificant after adjustment for confounders, whereas positive associations between soluble vascular cell adhesion molecule-1 and total adiponectin became significant only after multivariate adjustment. CONCLUSIONS: Total and HMW adiponectin are inversely associated with markers of insulin secretion/insulinemia, endothelial function, and inflammation. Resistin is positively associated only with markers of inflammation.
Authors: Jennifer H Lee; Jean L Chan; Nikos Yiannakouris; Meropi Kontogianni; Elizabeth Estrada; Richard Seip; Christine Orlova; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2003-10 Impact factor: 5.958
Authors: Subodh Verma; Shu-Hong Li; Chao-Hung Wang; Paul W M Fedak; Ren-Ke Li; Richard D Weisel; Donald A G Mickle Journal: Circulation Date: 2003-07-21 Impact factor: 29.690
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Lisa Patel; Amy C Buckels; Ian J Kinghorn; Paul R Murdock; Joanna D Holbrook; Christopher Plumpton; Colin H Macphee; Stephen A Smith Journal: Biochem Biophys Res Commun Date: 2003-01-10 Impact factor: 3.575
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Joanne Kotsopoulos; Shelley S Tworoger; Hannia Campos; Fung-Lung Chung; Charles V Clevenger; Adrian A Franke; Christos S Mantzoros; Vincent Ricchiuti; Walter C Willett; Susan E Hankinson; A Heather Eliassen Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Anand Vaidya; Luminita Pojoga; Patricia C Underwood; John P Forman; Paul N Hopkins; Gordon H Williams; Jonathan S Williams Journal: Clin Endocrinol (Oxf) Date: 2011-03 Impact factor: 3.478
Authors: Ida Soto-Rodríguez; Alfonso Alexander-Aguilera; Antonio Zamudio-Pérez; Mireya Camara-Contreras; Guillermo Hernandez-Diaz; Hugo S Garcia Journal: Inflammation Date: 2012-08 Impact factor: 4.092